NCT03823352 - Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 20, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG

Antroquinonol

Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.

Trial Locations (2)

125101

City Clinical Hospital n.a. S.P.Botkin, Moscow

300053

Tula Regional Clinical Hospital, Tula